156 research outputs found
Az ösztrogén receptor gén polimorfizmus és a lipoproteinek, valamint egyes alvadási tényezők kapcsolata. Az ösztrogén receptor gén polimorfizmus szerepe a cardiovascularis betegségek rizikójában = Association of estrogen receptor gene polymorphisms with serum lipoprotein levels and hemostatic factors. The role of estrogen receptor gene polymorphisms in the risk of cardiovascular diseases
Az ösztrogĂ©nek az ösztrogĂ©n receptor ?-n keresztĂĽl számos (rĂ©szben lokális, rĂ©szben szisztĂ©más) hatást gyakorolnak a cardiovascularis rendszerre. Kutatási projektĂĽnk keretĂ©ben azt vizsgáltuk, hogy az ösztrogĂ©n receptor ? gĂ©n PvuII (ESR1c.454-397T>C) Ă©s XbaI (ESR1c.454-351A>G) polimorfizmusa mutat-e összefĂĽggĂ©st az ischaemiás stroke, a koszorúér betegsĂ©g Ă©s a praeeclampsia kockázatával, illetve, hogy befolyásol-e ösztrogĂ©n-fĂĽggĹ‘ lipid, alvadási Ă©s gyulladásos tĂ©nyezĹ‘ket reproduktĂv korĂş, egĂ©szsĂ©ges egyĂ©nekben.
Tanulmányunkban az ösztrogĂ©n receptor ? PvuII Ă©s XbaI polimorfizmusa Ă©s az ischaemiás stroke, illetve koszorúér betegsĂ©g között nem találtunk asszociáciĂłt. Az XbaI polimorfizmus azonban összefĂĽggĂ©st mutatott a szĂ©rum lipoprotein(a) szintekkel reproduktĂv korĂş egĂ©szsĂ©ges egyĂ©nekben. ReproduktĂv korĂş egĂ©szsĂ©ges nĹ‘kben a PvuII polimorfizmus a szĂ©rum összkoleszterin, mĂg az XbaI polimorfizmus a szĂ©rum összkoleszterin Ă©s LDL-koleszterin szintekkel mutatott asszociáciĂłt. TerhessĂ©gben a T-A haplotĂpus homozigĂłta hordozĂłinak rizikĂłja szignifikánsan nagyobb volt praeeclampsiára a más genotĂpus-kombináciĂłt hordozĂłkkal összehasonlĂtva. Praeeclampsiás terhesekben az ESR1 XbaI polimorfizmus az intrauterin növekedĂ©si retardatiĂłval mutatott összefĂĽggĂ©st. A kĂ©t polimorfizmus szĂ©rum lipid szintekre, valamint a praeeclampsia Ă©s a magzati sorvadás kockázatára gyakorolt hatásának pontos molekuláris mechanizmusa azonban mĂ©g nem ismert. | Estrogen has several ESR1-mediated effects - including both direct effects and systemic effects - on the cardiovascular system. The aim of our research project was to determine whether two polymorphisms of the ESR1 gene (ESR1 c.454-397T>C: PvuII restriction site and c.454-351A>G: XbaI restriction site) are associated with ischemic stroke, coronary artery disease or preeclampsia. We also investigated whether these polymorphisms can influence estrogen-dependent lipid, haemostatic and inflammatory variables in healthy Caucasian women and men of reproductive age.
According to our results, the ESR1 PvuII and XbaI polymorphisms were not associated with ischemic stroke or coronary artery disease. In healthy subjects of reproductive age, the ESR1 XbaI polymorphism affected serum lipoprotein(a) concentrations. In healthy women of reproductive age, the PvuII polymorphism was associated with serum total cholesterol levels, whereas the XbaI polymorphism affected serum total cholesterol and LDL cholesterol concentrations. In pregnancy, the homozygous T-A haplotype carriers of ESR1 PvuII and XbaI polymorphisms showed an increased risk of preeclampsia. In addition, the ESR1 XbaI polymorphism was associated with fetal growth restriction in preeclamptic patients. However, the molecular mechanisms by which the two polymorphisms affect serum lipid levels and the risk of preeclampsia and fetal growth restriction are still unclear
Korszerű lipidcsökkentő kezelés
Considerable evidence suggests that "the lower the better" is a reasonable approach for reducing cardiovascular risk by lowering LDL cholesterol levels. Despite the reduction in cardiovascular events and mortality achieved by statin therapy, significant residual risk remains, especially in severe hereditary hypercholesterolemia, such as familial hypercholesterolemia. Some new strategies to achieve even lower LDL levels are now available, including the addition of cholesterol absorption inhibitor ezetimibe, and the recently available Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. In addition, new LDL drugs may be effectively administrated in those individuals who are unable to tolerate statins. The authors summarize the efficacy and clinical indications of these new agents and review the currently available guidelines
- …